ADHDNCT04504474
Network Analysis of Adult MDD and ADHD
An observational study of ADHD, run by Health Sciences North Research Institute at 1 site in Canada.
Trial summary
The study is an investigation to determine co-morbid symptoms between adult major depressive disorder (MDD) and adult attention-deficit hyperactivity disorder (ADHD) using a novel statistical technique called network analysis. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- ADHD
- How many people
- 1 participants
- Where
- 1 siteCanada
- Study dates
- 21 Jun 2018to 4 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: We will gather a recruitment of 500 male and female outpatients from the Psychiatric Outpatient Clinic at Kirkwood Site attached to Health Sciences North.
Who may be able to join
- participants have a diagnosis of MDD or ADHD or both
- participants are competent to consent to the study
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
Canada1 site
Kirkwood Site - Health Sciences North
Greater Sudbury, Ontario, P3E 1X3
About this study
Official title: Network Analysis of Co-morbid Symptoms of Adult Major Depressive Disorder and Attention-deficit Hyperactivity Disorder in an Outpatient Population
The study is an investigation to determine co-morbid symptoms between adult major depressive disorder (MDD) and adult attention-deficit hyperactivity disorder (ADHD) using a novel statistical technique called network analysis.
- Conditions
- ADHD
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What is being measured
The primary outcome is the main question the study is designed to answer.
Co-morbidity
Characterize the ADHD/MDD symptom network in a psychiatric outpatient setting comprised of adults
Measured: September 8, 2021
Network reliability
Determine the stability and reliability of this network
Measured: September 8, 2021
Central symptoms
Determine the central symptoms that lead to co-activation of ADHD/MDD clusters
Measured: September 8, 2021
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2020
- Study start21 Jun 2018
- Primary completion4 Dec 2023
- Study completion4 Dec 2023
Why it stopped: The Health Sciences North Research Ethics Board (HSN REB) has recommended termination of approval for the research project, because it has surpassed the stated date of expiry for renewal.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ADHDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Health Sciences North Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04504474
- Sponsor's protocol ID
- 18-056
- Status last verified
- Aug 2020
- First submitted
- 5 Aug 2020
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: None of the IPD will be shared with other researchers
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Network Analysis of Co-morbid Symptoms of Adult Major Depressive Disorder and Attention-deficit Hyperactivity Disorder in an Outpatient Population
- ClinicalTrials.gov ID
- NCT04504474
- Acronym / sponsor ID
- 18-056
- Conditions
- ADHD
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: The Health Sciences North Research Ethics Board (HSN REB) has recommended termination of approval for the research project, because it has surpassed the stated date of expiry for renewal.
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Health Sciences North Research InstituteUniversity, hospital or other
- Study start
- 21 Jun 2018 (actual)
- Primary completion
- 4 Dec 2023 (actual)
- Study completion
- 4 Dec 2023 (actual)
- First posted
- 7 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is an investigation to determine co-morbid symptoms between adult major depressive disorder (MDD) and adult attention-deficit hyperactivity disorder (ADHD) using a novel statistical technique called network analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- We will gather a recruitment of 500 male and female outpatients from the Psychiatric Outpatient Clinic at Kirkwood Site attached to Health Sciences North.
Key inclusion criteria (2 listed)
- participants have a diagnosis of MDD or ADHD or both
- participants are competent to consent to the study
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Co-morbidity
Time frame: September 8, 2021
Characterize the ADHD/MDD symptom network in a psychiatric outpatient setting comprised of adults
Network reliability
Time frame: September 8, 2021
Determine the stability and reliability of this network
Central symptoms
Time frame: September 8, 2021
Determine the central symptoms that lead to co-activation of ADHD/MDD clusters
Results and safety
The study was stopped early (reason given: The Health Sciences North Research Ethics Board (HSN REB) has recommended termination of approval for the research project, because it has surpassed the stated date of expiry for renewal.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- Individual participant dataSharing planned: No. None of the IPD will be shared with other researchers
Related trials for ADHD
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
ADHD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ADHD, run by Health Sciences North Research Institute at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The Health Sciences North Research Ethics Board (HSN REB) has recommended termination of approval for the research project, because it has surpassed the stated date of expiry for renewal.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Co-morbidity (time frame: September 8, 2021). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.